The following is a summary of “Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

High-risk, non-muscle-invasive bladder cancer is defined as ... of bacille Calmette–Guérin (BCG). Peak induction of cytokines occurs around the fourth treatment, and is sustained through ...

The company holds several patents for the composition and use of BCG combined with Anktiva in bladder cancer treatment. The ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

There are few treatment options for patients who develop BCG-unresponsive bladder cancer, which raises the risk of the cancer spreading throughout the body. Around 40% of patients don’t respond ...

But when cancer develops, it often uses tactics to fool the immune ... In this trial, the RUTI vaccine was administered alongside the standard BCG treatment. The results were promising: RUTI ...

Cretostimogene monotherapy achieves a 75.5% complete response rate in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients. The treatment maintains a 46% complete response at 12 ...

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration ...

Supply shortages of TICE BCG in the U.S. have become a significant impediment to the treatment of bladder cancer patients. In a recent Sermo survey of 100 U.S. urologists, 57 percent indicated ...

Brain cancer remains one of medicine’s most formidable challenges, requiring sophisticated treatment approaches tailored to each patient’s specific situation. With advances in surgical ...

Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with Light-Activated Ruvidar(TM) ...